tbuckley/cabot-search huggingface dataset:
Repeatability of Pulmonary Quantitative Computed Tomography Measurements in Chronic Obstructive Pulmonary Disease
Authors: Amin Motahari, R. Graham Barr, MeiLan K. Han, Wayne H. Anderson, Igor Barjaktarevic, Eugene R. Bleecker, Alejandro P. Comellas, Christopher B. Cooper, David J. Couper, Nadia N. Hansel, Richard E. Kanner, Ella A. Kazerooni, David A. Lynch, Fernando J. Martinez, John D. Newell, Joyce D. Schroeder, Benjamin M. Smith, Prescott G. Woodruff, Eric A. Hoffman, Neil E. Alexis, Wayne H. Anderson, Mehrdad Arjomandi, Igor Barjaktarevic, R. Graham Barr, Patricia Basta, Lori A. Bateman, Christina Bellinger, Surya P. Bhatt, Eugene R. Bleecker, Richard C. Boucher, Russell P. Bowler, Russell G. Buhr, Stephanie A. Christenson, Alejandro P. Comellas, Christopher B. Cooper, David J. Couper, Gerard J. Criner, Ronald G. Crystal, Jeffrey L. Curtis, Claire M. Doerschuk, Mark T. Dransfield, M. Bradley Drummond, Christine M. Freeman, Craig Galban, Katherine Gershner, MeiLan K. Han, Nadia N. Hansel, Annette T. Hastie, Eric A. Hoffman, Yvonne J. Huang, Robert J. Kaner, Richard E. Kanner, Mehmet Kesimer, Eric C. Kleerup, Jerry A. Krishnan, Wassim W. Labaki, Lisa M. LaVange, Stephen C. Lazarus, Fernando J. Martinez, Merry-Lynn McDonald, Deborah A. Meyers, Wendy C. Moore, John D. Newell, Elizabeth C. Oelsner, Jill Ohar, Wanda K. O’Neal, Victor E. Ortega, Robert Paine, Laura Paulin, Stephen P. Peters, Cheryl Pirozzi, Nirupama Putcha, Sanjeev Raman, Stephen I. Rennard, Donald P. Tashkin, J. Michael Wells, Robert A. Wise, Prescott G. Woodruff, Lisa Postow, Lisa Viviano
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

"Repeatability of Pulmonary Quantitative Computed Tomography Measurements in Chronic Obstructive Pulmonary Disease." American Journal of Respiratory and Critical Care Medicine, 208(6), pp. 657–665
Multifaceted effects of obesity on cancer immunotherapies: Bridging preclinical models and clinical data
Authors: Logan V. Vick, Robert J. Canter, Arta M. Monjazeb, William J. Murphy
Journal: Seminars in Cancer Biology (2023)

Obesity, defined by excessive body fat, is a highly complex condition affecting numerous physiological processes, such as metabolism, proliferation, and cellular homeostasis. These multifaceted effects impact cells and tissues throughout the host, including immune cells as well as cancer biology. Because of the multifaceted nature of obesity, common parameters used to define it (such as body mass index in humans) can be problematic, and more nuanced methods are needed to characterize the pleiotropic metabolic effects of obesity. Obesity is well-accepted as an overall negative prognostic factor for cancer incidence, progression, and outcome. This is in part due to the meta-inflammatory and immunosuppressive effects of obesity. Immunotherapy is increasingly used in cancer therapy, and there are many different types of immunotherapy approaches. The effects of obesity on immunotherapy have only recently been studied with the demonstration of an "obesity paradox", in which some immune therapies have been demonstrated to result in greater efficacy in obese subjects despite the direct adverse effects of obesity and excess body fat acting on the cancer itself. The multifactorial characteristics that influence the effects of obesity (age, sex, lean muscle mass, underlying metabolic conditions and drugs) further confound interpretation of clinical data and necessitate the use of more relevant preclinical models mirroring these variables in the human scenario. Such models will allow for more nuanced mechanistic assessment of how obesity can impact, both positively and negatively, cancer biology, host metabolism, immune regulation, and how these intersecting processes impact the delivery and outcome of cancer immunotherapy.
Clinical efficacy of guided bone regeneration in peri‐implantitis defects. A network meta‐analysis
Authors: Ausra Ramanauskaite, Kathrin Becker, Emilio A. Cafferata, Frank Schwarz
Journal: Periodontology 2000 (2023)

Abstract Guided bone regeneration (GBR) at peri‐implantitis‐related bone defects involves the placement of bone‐filler particles in the intrabony defects and the application of a barrier membrane. The efficacy of different GBR‐supported reconstructive measures as well as their potential superiority compared to non‐GBR‐supported treatment strategies for bone defects at peri‐implantitis sites, however, remains unclear. Therefore, this analysis was designed to evaluate the long‐term (≥12 months) clinical efficacy of GBR‐supported reconstructive surgical therapy for peri‐implantitis‐related bone defects. In terms of resolving inflammation, the implementation of GBR protocols applying xenogenic bone substitutes yielded a higher reduction of bleeding on probing and probing depth value compared to the GBR protocol applying autogenous bone. Furthermore, for the changes in bleeding on probing and probing depths, GBR approaches using xenogenic bone showed superiority over the non‐GBR treatments. Xenogenic bone with or without a barrier membrane was associated with improved radiographic bone levels and less soft tissue recession compared to the use of a GBR protocol implementing autogenous bone. Nonetheless, when interpreting this findings, the limited number of available studies with low to serious risk of bias and the short follow‐up periods limited to 12 months should be considered.
Depressive Symptoms Longitudinally Mediate the Effect of Hyperglycemia on Memory Decline in Type 2 Diabetes
Authors: A. Zarina Kraal, Vicki L. Ellingrod, Laura B. Zahodne
Journal: Diabetes Care (2023)

We sought to examine the mediating role of changes in depressive symptoms in the association between chronic hyperglycemia and longitudinal cognition in a sample of older adults with type 2 diabetes (T2D).
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
Authors: Elizabeth R. Plimack, Thomas Powles, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Tom Waddell, Boris Alekseev, Frédéric Pouliot, Bohuslav Melichar, Denis Soulières, Delphine Borchiellini, Raymond S. McDermott, Ihor Vynnychenko, Yen-Hwa Chang, Satoshi Tamada, Michael B. Atkins, Chenxiang Li, Rodolfo Perini, L. Rhoda Molife, Jens Bedke, Brian I. Rini
Journal: European Urology (2023)
The impact of transition to a digital hospital on medication errors (TIME study)
Authors: Teyl Engstrom, Elizabeth McCourt, Martin Canning, Katharine Dekker, Panteha Voussoughi, Oliver Bennett, Angela North, Jason D. Pole, Peter J. Donovan, Clair Sullivan
Journal: npj Digital Medicine (2023)

Digital transformation in healthcare improves the safety of health systems. Within our health service, a new digital hospital has been established and two wards from a neighbouring paper-based hospital transitioned into the new digital hospital. This created an opportunity to evaluate the impact of complete digital transformation on medication safety. Here we discuss the impact of transition from a paper-based to digital hospital on voluntarily reported medication incidents and prescribing errors. This study utilises an interrupted time-series design and takes place across two wards as they transition from a paper to a digital hospital. Two data sources are used to assess impacts on medication incidents and prescribing errors: (1) voluntarily reported medication incidents and 2) a chart audit of medications prescribed on the study wards. The chart audit collects data on procedural, dosing and therapeutic prescribing errors. There are 588 errors extracted from incident reporting software during the study period. The average monthly number of errors reduces from 12.5 pre- to 7.5 post-transition (p < 0.001). In the chart audit, 5072 medication orders are reviewed pre-transition and 3699 reviewed post-transition. The rates of orders with one or more error reduces significantly after transition (52.8% pre- vs. 15.7% post-, p < 0.001). There are significant reductions in procedural (32.1% pre- vs. 1.3% post-, p < 0.001), and dosing errors (32.3% pre- vs. 14% post-, p < 0.001), but not therapeutic errors (0.6% pre- vs. 0.7% post-, p = 0.478). Transition to a digital hospital is associated with reductions in voluntarily reported medication incidents and prescribing errors.
Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality
Authors: John H. Kempen, Craig W. Newcomb, Terri L. Washington, C. Stephen Foster, Lucia Sobrin, Jennifer E. Thorne, Douglas A. Jabs, Eric B. Suhler, James T. Rosenbaum, H. Nida Sen, Grace A. Levy-Clarke, Robert B. Nussenblatt, Nirali P. Bhatt, Careen Y. Lowder, Debra A. Goldstein, Yannek I. Leiderman, Nisha R. Acharya, Gary N. Holland, Russell W. Read, James P. Dunn, Kurt A. Dreger, Pichaporn Artornsombudh, Hosne A. Begum, Tonetta D. Fitzgerald, Srishti Kothari, Abhishek R. Payal, Ebenezer Daniel, Sapna S. Gangaputra, R. Oktay Kaçmaz, Teresa L. Liesegang, Siddharth S. Pujari, Naira Khachatryan, Armin Maghsoudlou, Hilkiah K. Suga, Clara M. Pak, Kathy J. Helzlsouer, Jeanine M. Buchanich
Journal: Ophthalmology (2023)
Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study
Authors: Niklas Worm Andersson, Emilia Myrup Thiesson, Jørgen Vinsløv Hansen, Anders Hviid
Journal: BMJ (2023)

To examine the association between the omicron adapted bivalent mRNA covid-19 booster vaccines received as a fourth dose and risk of adverse events.Nationwide cohort study.Denmark.2 225 567 adults aged ≥50 years who received three covid-19 vaccine doses during the study period, 1 January 2021 to 10 December 2022.The main outcome measure was rates of hospital visits for 27 different adverse events in a 28 day main risk period after vaccination with a bivalent omicron adapted mRNA booster vaccine as a fourth dose compared with reference period rates from day 29 after the third or fourth vaccine dose and onward.1 740 417 adults (mean age 67.8 years, standard deviation 10.7 years) received a bivalent mRNA vaccine as a fourth dose. Fourth dose vaccination with a bivalent mRNA vaccine was not associated with a statistically significant increased rate of any of the 27 adverse outcomes within 28 days (eg, incidence rate ratio of 0.95, 95% confidence interval of 0.87 to 1.04 for ischaemic cardiac events based on 672 v 9992 events during the compared 28 day risk and reference period, respectively), nor when analysed according to age, sex, or vaccine type, or when using alternative analytical approaches. However, post hoc analysis detected signals for myocarditis (statistically significant in female participants), although the outcome was rare and findings were based on few cases. No risk of cerebrovascular infarction was found (incidence rate ratio 0.95, 95% confidence interval 0.87 to 1.05; 644 v 9687 events).The use of bivalent mRNA vaccines as a fourth vaccine dose against covid-19 was not associated with an increased risk of 27 different adverse events in adults aged ≥50 years.
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
Authors: Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, Dhwani Patel, Oscar B. Lahoud, Heather J. Landau, David J. Chung, Gunjan L. Shah, Michael Scordo, Sergio A. Giralt, Alexander Lesokhin, Saad Z. Usmani, Ola Landgren, Neha Korde
Journal: Blood Cancer Journal (2023)

Abstract Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary endpoint was progression-free survival (PFS). Of 389 patients with newly diagnosed multiple myeloma, 198 received VRd and 191 received KRd. Median PFS was not reached (NR) in both groups; 5-year PFS was 56% (95%CI, 48–64%) for VRd and 67% (60–75%) for KRd ( P = 0.027). Estimated 5-year EFS was 34% (95%CI, 27–42%) for VRd and 52% (45–60%) for KRd ( P &lt; 0.001) with corresponding 5-year OS of 80% (95%CI, 75–87%) and 90% (85–95%), respectively ( P = 0.053). For standard-risk patients, 5-year PFS was 68% (95%CI, 60–78%) for VRd and 75% (65–85%) for KRd ( P = 0.20) with 5-year OS of 87% (95%CI, 81–94%) and 93% (87–99%), respectively ( P = 0.13). For high-risk patients, median PFS was 41 months (95%CI, 32.8–61.1) for VRd and 70.9 months (58.2-NR) for KRd ( P = 0.016). Respective 5-year PFS and OS were 35% (95%CI, 24–51%) and 69% (58–82%) for VRd and 58% (47–71%) and 88% (80–97%, P = 0.044) for KRd. Overall, KRd resulted in improved PFS and EFS with a trend toward improved OS compared to VRd with associations primarily driven by improvements in outcome for high-risk patients.
The potential role of the microbiota in prostate cancer pathogenesis and treatment
Authors: Nicolò Pernigoni, Christina Guo, Lewis Gallagher, Wei Yuan, Manuel Colucci, Martina Troiani, Lei Liu, Luisa Maraccani, Ilaria Guccini, Denis Migliorini, Johann de Bono, Andrea Alimonti
Journal: Nature Reviews Urology (2023)
Atmosphere-inspired multilayered nanoarmor with modulable protection and delivery of Interleukin-4 for inflammatory microenvironment modulation
Authors: Xin Ge, Junfeng Hu, Yuan Peng, Zhuo Zeng, Danfeng He, Xilan Li, Yajie Chen, Gaoxing Luo, Jun Deng, Zhigang Xu, Song He
Journal: Biomaterials (2023)
Protecting vulnerable patient populations from climate hazards: the role of the nation’s cancer centers
Authors: Zelde Espinel, James M Shultz, Vanina Pavia Aubry, Omar Muñoz Abraham, Qinjin Fan, Tracy E Crane, Liora Sahar, Leticia M Nogueira
Journal: JNCI Journal of the National Cancer Institute (2023)

Abstract Individuals diagnosed with cancer are a vulnerable population during disasters. Emergency preparedness efforts are crucial for meeting the health and safety needs of patients, health-care professionals, health-care facilities, and communities before, during, and after a disaster. Recognizing the importance of advancing emergency preparedness expertise to cancer control efforts nationwide, especially in the era of climate change, we searched National Cancer Institute–designated cancer centers’ websites to examine emergency preparedness information sharing and evidence of research efforts focused on disaster preparedness. Of 71 centers, 56 (78.9%) presented some emergency preparedness information, and 36 (50.7%) presented information specific to individuals diagnosed with cancer. Only 17 (23.9%) centers provided emergency preparedness information for climate-driven disasters. Informed by these data, this commentary describes an opportunity for cancer centers to lead knowledge advancement on an important aspect of climate change adaptation: disaster preparedness.
Misdiagnosis Might Harm up to 800 000 US Patients Annually
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Using EEG to Monitor Brain Wave Transitions Could Reduce Postoperative Cognitive Issues
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Free COVID-19 Vaccinations on the Way for Uninsured Adults
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Experts Disagree About Aspartame’s “Possibly Carcinogenic” Status
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The 2023 ACR/<scp>EULAR</scp> Classification Criteria for Calcium Pyrophosphate Deposition Disease
Authors: Abhishek Abhishek, Sara K. Tedeschi, Tristan Pascart, Augustin Latourte, Nicola Dalbeth, Tuhina Neogi, Amy Fuller, Ann Rosenthal, Fabio Becce, Thomas Bardin, Hang Korng Ea, Georgios Filippou, John FitzGerald, AnnaMaria Iagnocco, Frédéric Lioté, Geraldine M. McCarthy, Roberta Ramonda, Pascal Richette, Francisca Sivera, Mariano Andres, Edoardo Cipolletta, Michael Doherty, Eliseo Pascual, Fernando Perez‐Ruiz, Alexander So, Tim L. Jansen, Minna J. Kohler, Lisa K. Stamp, Janeth Yinh, Antonella Adinolfi, Uri Arad, Thanda Aung, Eva Benillouche, Alessandra Bortoluzzi, Jonathan Dau, Ernest Maningding, Meika A. Fang, Fabiana A. Figus, Emilio Filippucci, Janine Haslett, Matthijs Janssen, Marian Kaldas, Maryann Kimoto, Kelly Leamy, Geraldine M. Navarro, Piercarlo Sarzi‐Puttini, Carlo Scirè, Ettore Silvagni, Silvia Sirotti, John R. Stack, Linh Truong, Chen Xie, Chio Yokose, Alison M. Hendry, Robert Terkeltaub, William J. Taylor, Hyon K. Choi
Journal: Arthritis & Rheumatology (2023)

Objective Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have developed the first‐ever validated classification criteria for symptomatic CPPD disease. Methods Supported by the ACR and EULAR, a multinational group of investigators followed established methodology to develop these disease classification criteria. The group generated lists of candidate items and refined their definitions, collected de‐identified patient profiles, evaluated strengths of associations between candidate items and CPPD disease, developed a classification criteria framework, and used multi‐criterion decision analysis to define criteria weights and a classification threshold score. The criteria were validated in an independent cohort. Results Among patients with joint pain, swelling, or tenderness (entry criterion) whose symptoms are not fully explained by an alternative disease (exclusion criterion), the presence of crowned dens syndrome or calcium pyrophosphate crystals in synovial fluid are sufficient to classify a patient as having CPPD disease. In the absence of these findings, a score &gt;56 points using weighted criteria, comprising clinical features, associated metabolic disorders, and results of laboratory and imaging investigations, can be used to classify as CPPD disease. These criteria had a sensitivity of 92.2% and specificity of 87.9% in the derivation cohort (190 CPPD cases, 148 mimickers), whereas sensitivity was 99.2% and specificity was 92.5% in the validation cohort (251 CPPD cases, 162 mimickers). Conclusion The 2023 ACR/EULAR CPPD disease classification criteria have excellent performance characteristics and will facilitate research in this field.